1. Home
  2. BNY vs MDWD Comparison

BNY vs MDWD Comparison

Compare BNY & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNY
  • MDWD
  • Stock Information
  • Founded
  • BNY 2001
  • MDWD 2000
  • Country
  • BNY United States
  • MDWD Israel
  • Employees
  • BNY N/A
  • MDWD N/A
  • Industry
  • BNY Trusts Except Educational Religious and Charitable
  • MDWD Medicinal Chemicals and Botanical Products
  • Sector
  • BNY Finance
  • MDWD Health Care
  • Exchange
  • BNY Nasdaq
  • MDWD Nasdaq
  • Market Cap
  • BNY 232.5M
  • MDWD 230.6M
  • IPO Year
  • BNY N/A
  • MDWD 2014
  • Fundamental
  • Price
  • BNY $9.61
  • MDWD $19.52
  • Analyst Decision
  • BNY
  • MDWD Strong Buy
  • Analyst Count
  • BNY 0
  • MDWD 2
  • Target Price
  • BNY N/A
  • MDWD $35.00
  • AVG Volume (30 Days)
  • BNY 52.7K
  • MDWD 55.2K
  • Earning Date
  • BNY 01-01-0001
  • MDWD 08-13-2025
  • Dividend Yield
  • BNY 3.93%
  • MDWD N/A
  • EPS Growth
  • BNY N/A
  • MDWD N/A
  • EPS
  • BNY N/A
  • MDWD N/A
  • Revenue
  • BNY N/A
  • MDWD $19,213,000.00
  • Revenue This Year
  • BNY N/A
  • MDWD $20.80
  • Revenue Next Year
  • BNY N/A
  • MDWD $26.92
  • P/E Ratio
  • BNY N/A
  • MDWD N/A
  • Revenue Growth
  • BNY N/A
  • MDWD N/A
  • 52 Week Low
  • BNY $8.60
  • MDWD $14.14
  • 52 Week High
  • BNY $10.80
  • MDWD $24.00
  • Technical
  • Relative Strength Index (RSI)
  • BNY 42.94
  • MDWD 44.07
  • Support Level
  • BNY $9.56
  • MDWD $18.50
  • Resistance Level
  • BNY $9.69
  • MDWD $19.87
  • Average True Range (ATR)
  • BNY 0.08
  • MDWD 0.63
  • MACD
  • BNY 0.01
  • MDWD -0.31
  • Stochastic Oscillator
  • BNY 26.32
  • MDWD 28.41

About BNY BlackRock New York Municipal Income Trust

Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: